A Multicenter, Randomized Phase III Study Comparing Platinum Combination Chemotherapy Plus Pembrolizumab With Platinum Combination Chemotherapy Plus Nivolumab and Ipilimumab for Treatment-Naive Advanced Non-Small Cell Lung Cancer Without Driver Gene Alterations: JCOG2007 (NIPPON Study)-论文-万方医学网

A Multicenter, Randomized Phase III Study Comparing Platinum Combination Chemotherapy Plus Pembrolizumab With Platinum Combination Chemotherapy Plus Nivolumab and Ipilimumab for Treatment-Naive Advanced Non-Small Cell Lung Cancer Without Driver Gene Alterations: JCOG2007 (NIPPON Study)

导出原文传递

翻译打印收藏纠错

作者： Shiraishi, Yoshimasa ^[1] ; Hakozaki, Taiki ^[2] ; Nomura, Shogo ^[3] ; Kataoka, Tomoko ^[4] ; Tanaka, Kentaro ^[5] ; Miura, Satoru ^[6] ; Sekino, Yuta ; Ando, Masahiko ; Horinouchi, Hidehito ; Ohe, Yuichiro ; Okamoto, Isamu

作者单位： Grad Sch Med Sci,Kyushu Univ ^[1] Dept Thorac Oncol & Resp Med,Komagome Hosp ^[2] Japan Clin Oncol Grp Data Ctr,Natl Canc Ctr ^[3] Dept Internal Med,Niigata Canc Ctr Hosp ^[4] Dept Adv Med,Nagoya Univ Hosp ^[5] Dept Thorac Oncol,Natl Canc Ctr ^[6]

关键词 Immune checkpoint inhibitor PD-1 CTLA-4 Overall survival Superiority SURVIVAL

发布时间 2022-09-01

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除